Outcomes of real‐world initiation of long‐acting injectable cabotegravir and rilpivirine ( LA ‐I CAB + RPV ) in individuals with viraemia: A systematic review of baseline characteristics, virological failure outcomes and discontinuations
HIV Medicine · 2026
DOI: 10.1111/hiv.70113 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift HIV Medicine, 2026. Verfasst von Alexa Elias und 4 weiteren Autor:innen. Beteiligte Einrichtung: SHARE Collaborative, Blizard Institute, Queen Mary University of London, London, UK. Hauptthemen laut MEDLINE: Rilpivirine, HIV Infections, Viremia, Pyridones. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ViiV Healthcare.
Abstract (Originalsprache)
Background
When using long‐acting injectable cabotegravir and rilpivirine (CAB + RPV) in individuals with viraemia, beyond small cohorts, little is known about baseline characteristics, virological failure outcomes, resistance emergence, re‐suppression and discontinuation.
Methods
We identified evidence from PubMed , EMBASE , Cochrane and conference abstract databases through 17 March 2025 to synthesize data from observational cohort studies ( OCS ) that reported on virological failure ( VF ) events in individuals with viraemia at initiation of LA ‐I CAB + RPV . We extracted data on baseline clinical and socio‐demographic characteristics, VF , resistance‐associated mutations ( RAMs ) at VF , post‐ VF regimen choice, re‐suppression and discontinuation.
Results
Across 14 cohorts including 561 individuals, there were 36 VF events ( OCS ‐level VF rate 0% ( n / N = 0/12, 0/12 and 0/10) to 25% ( n / N = 3/12)). VF definitions varied. 6/14 OCS ( n = 436) reported on baseline CD4 count, 13/14 ( n = 543) on baseline viral load and 7/14 ( n = 459) on socio‐demographic characteristics. Among the 14 VF events with genotypic information available at VF , NNRTI RAMs were identified in 13/14 individuals, INI RAMs in 9/14 and dual‐class resistance in 8/14 individuals. Post‐ VF regimens were reported for 16/36 individuals with VF and included lenacapavir ( LEN )‐based regimens, protease inhibitor ( PI )‐based regimens or LA ‐I CAB + RPV continuation. Re‐suppression outcomes were described in 10 VF events: re‐suppression occurred in 5/10.
Conclusions
In OCS , the follow‐up duration was short and VF definitions were highly variable, with few cohorts reporting VF outcomes in people with baseline VL >10 000 c/ mL . VF was frequently accompanied by resistance. Post‐ VF regimens varied, and their success was unclear due to the small sample size.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SHARE Collaborative, Blizard Institute, Queen Mary University of London, London, UK.
- Pandemic Sciences Institute, University of Oxford, Oxford, UK.
- Barts Health NHS Trust, London, UK.
ORCID-Profile: Alexa Elias, Chloé Pasin, Chloe M Orkin
Förderung
- ViiV Healthcare
Zitieren
APA
Elias, A., Pasin, C., Smuk, M., Paterson, A., & Orkin, C. M. (2026). Outcomes of real‐world initiation of long‐acting injectable cabotegravir and rilpivirine ( LA ‐I CAB + RPV ) in individuals with viraemia: A systematic review of baseline characteristics, virological failure outcomes and discontinuations. HIV Medicine. https://doi.org/10.1111/hiv.70113
Vancouver
Elias A, Pasin C, Smuk M, Paterson A, Orkin CM. Outcomes of real‐world initiation of long‐acting injectable cabotegravir and rilpivirine ( LA ‐I CAB + RPV ) in individuals with viraemia: A systematic review of baseline characteristics, virological failure outcomes and discontinuations. HIV Medicine. 2026. doi:10.1111/hiv.70113
BibTeX
@article{Elias2026,
author = {Elias, Alexa and Pasin, Chloé and Smuk, Melanie and Paterson, Amy and Orkin, Chloe M},
title = {Outcomes of real‐world initiation of long‐acting injectable cabotegravir and rilpivirine ( LA ‐I CAB + RPV ) in individuals with viraemia: A systematic review of baseline characteristics, virological failure outcomes and discontinuations},
journal = {HIV Medicine},
year = {2026},
doi = {10.1111/hiv.70113}
}
EUVIMED